Oramed Pharmaceuticals Statistics Share Statistics Oramed Pharmaceuticals has 40.85M
shares outstanding. The number of shares has increased by 0.2%
in one year.
Shares Outstanding 40.85M Shares Change (YoY) 0.2% Shares Change (QoQ) 1.34% Owned by Institutions (%) 19% Shares Floating 32.66M Failed to Deliver (FTD) Shares 997 FTD / Avg. Volume 1.34%
Short Selling Information The latest short interest is 404.34K, so 0.99% of the outstanding
shares have been sold short.
Short Interest 404.34K Short % of Shares Out 0.99% Short % of Float 1.14% Short Ratio (days to cover) 6.86
Valuation Ratios The PE ratio is 16.86 and the forward
PE ratio is -1.67.
Oramed Pharmaceuticals's PEG ratio is
-0.15.
PE Ratio 16.86 Forward PE -1.67 PS Ratio 69.5 Forward PS 95.4 PB Ratio 0.57 P/FCF Ratio -8.83 PEG Ratio -0.15
Financial Ratio History Enterprise Valuation Oramed Pharmaceuticals has an Enterprise Value (EV) of 135.69M.
EV / Sales 101.26 EV / EBITDA -8.71 EV / EBIT -13.18 EV / FCF -12.86
Financial Position The company has a current ratio of 3.06,
with a Debt / Equity ratio of 0.32.
Current Ratio 3.06 Quick Ratio 3.06 Debt / Equity 0.32 Debt / EBITDA -3.31 Debt / FCF -4.89 Interest Coverage -4.4
Financial Efficiency Return on Equity is 3.37% and Return on Invested Capital is -7.21%.
Return on Equity 3.37% Return on Assets 2.51% Return on Invested Capital -7.21% Revenue Per Employee $103.08K Profits Per Employee $425K Employee Count 13 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -9.91% in the
last 52 weeks. The beta is 1.6, so Oramed Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.6 52-Week Price Change -9.91% 50-Day Moving Average 2.17 200-Day Moving Average 2.27 Relative Strength Index (RSI) 44.38 Average Volume (20 Days) 74,514
Income Statement In the last 12 months, Oramed Pharmaceuticals had revenue of 1.34M
and earned 5.53M
in profits. Earnings per share was 0.14.
Revenue 1.34M Gross Profit 1.34M Operating Income -15.77M Net Income 5.53M EBITDA -15.57M EBIT 7.13M Earnings Per Share (EPS) 0.14
Full Income Statement Balance Sheet The company has 9.05M in cash and 51.62M in
debt, giving a net cash position of -42.57M.
Cash & Cash Equivalents 9.05M Total Debt 51.62M Net Cash -42.57M Retained Earnings -157.56M Total Assets 165.08M Working Capital 137.5M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -10.29M
and capital expenditures -254K, giving a free cash flow of -10.55M.
Operating Cash Flow -10.29M Capital Expenditures -254K Free Cash Flow -10.55M FCF Per Share -0.26
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -1176.79% and 412.31%.
Gross Margin 100% Operating Margin -1176.79% Pretax Margin 379.7% Profit Margin 412.31% EBITDA Margin -1162.16% EBIT Margin -1176.79% FCF Margin -787.24%
Dividends & Yields ORMP does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield 5.93% FCF Yield -11.33%
Dividend Details Analyst Forecast Currently there are no analyst rating for ORMP.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number 3.54 Graham Upside 69.38%
Stock Splits The last stock split was on Jan 23, 2013. It was a
backward
split with a ratio of 1:12.
Last Split Date Jan 23, 2013 Split Type backward Split Ratio 1:12
Scores Altman Z-Score 5.44 Piotroski F-Score 4
